Incorporated in 1983, Parenteral Drugs Ltd is engaged in Manufacturing and Trading of Pharmaceutical Products
The Hon’ble NCLT, Mumbai has approved the resolution plan for Parenteral Drugs (India) Ltd. submitted by IHL Lifesciences Private Limited, which provides for delisting shares with NIL value. The resolution plan outlines payments including ₹3.4 Cr for CIRP costs and ₹57.55 Cr for secured creditors, translating to a recovery of...
The Hon’ble NCLT has approved the resolution plan proposed by IHL Lifesciences Private Limited for Parenteral Drugs (India) Ltd as part of its corporate insolvency resolution process (CIRP). The plan includes settling INR 57.55 crore (cr) for secured financial creditors and 100% payments for employee dues and EPFO obligations, signifying...
The Hon’ble NCLT has approved the resolution plan for Parenteral Drugs (India) Ltd., submitted by IHL Lifesciences Private Limited. Under the plan, total claims of INR 1,17,93.09 lakh will see a recovery of approximately 4.91%, with a significant focus on operational creditors, receiving 100% of their claims. The infusion of...
The Hon’ble NCLT has approved the resolution plan for Parenteral Drugs (India) Ltd. as part of its corporate insolvency resolution process (CIRP). This approval indicates a pathway for the company to stabilize and potentially restore operations post-insolvency, which may enhance its financial health and governance structures. Investors might view this...